The Experts below are selected from a list of 192 Experts worldwide ranked by ideXlab platform
Urs Giger - One of the best experts on this subject based on the ideXlab platform.
-
alloimmunization of a dog Erythrocyte Antigen 1 dog transfused with weakly dog Erythrocyte Antigen 1 blood
Journal of Veterinary Internal Medicine, 2019Co-Authors: Maryline Guidetti, Isabelle Goythollot, Catherine Boisvineau, Urs GigerAbstract:Background Acute hemolytic transfusion reactions because of dog Erythrocyte Antigen (DEA) 1 sensitization after mismatched transfusions are serious complications. Dog Erythrocyte Antigen 1 expression varies from negative to weakly to strongly positive. Objectives To assess alloimmunization after transfusion of weakly DEA 1+ blood to a DEA 1- dog. Animals One DEA 1- recipient and 1 weakly DEA 1+ donor, and 106 control dogs. Methods Long-term follow-up study. Matched for DEA 3, 4, 5, and 7, Dal, and Kai 1 and 2, weakly DEA 1+ donor packed red blood cells (RBCs) were transfused 3 times (0.45 mL/kg at Day 0, 16, and 37) to a DEA 1- recipient. Alloantibodies against RBCs from donor and 106 controls were determined in recipient's plasma samples using a commercial antiglobulin-enhanced immunochromatographic strip and gel tube crossmatches. Alloantibody titers were determined. Results The DEA 1- recipient was sensitized after 16 days to ≥1657 days after transfusion to weakly DEA 1+ and otherwise matched RBCs. Strong to moderate crossmatch incompatibilities were observed between recipient's plasma and all 61 DEA 1+ crossmatched controls. Moderate to weak incompatibilities were also observed to DEA 1- controls. Anti-DEA 1 and other alloantibodies were detected over the 4.5 year observation period. Conclusions and clinical importance Blood from a weakly DEA 1+ donor induces a strong and durable alloimmunization in a DEA 1- recipient dog. Additional alloantibodies developed against yet to be defined RBC Antigens. Those results support the recommendation of typing dogs against DEA 1, considering weakly DEA 1+ as immunogenic, and crossmatching all previously transfused dogs.
-
Alloimmunization of a dog Erythrocyte Antigen 1− dog transfused with weakly dog Erythrocyte Antigen 1+ blood
Journal of veterinary internal medicine, 2019Co-Authors: Maryline Guidetti, Catherine Boisvineau, Isabelle Goy-thollot, Urs GigerAbstract:Acute hemolytic transfusion reactions because of dog Erythrocyte Antigen (DEA) 1 sensitization after mismatched transfusions are serious complications. Dog Erythrocyte Antigen 1 expression varies from negative to weakly to strongly positive. To assess alloimmunization after transfusion of weakly DEA 1+ blood to a DEA 1- dog. One DEA 1- recipient and 1 weakly DEA 1+ donor, and 106 control dogs. Long-term follow-up study. Matched for DEA 3, 4, 5, and 7, Dal, and Kai 1 and 2, weakly DEA 1+ donor packed red blood cells (RBCs) were transfused 3 times (0.45 mL/kg at Day 0, 16, and 37) to a DEA 1- recipient. Alloantibodies against RBCs from donor and 106 controls were determined in recipient's plasma samples using a commercial antiglobulin-enhanced immunochromatographic strip and gel tube crossmatches. Alloantibody titers were determined. The DEA 1- recipient was sensitized after 16 days to ≥1657 days after transfusion to weakly DEA 1+ and otherwise matched RBCs. Strong to moderate crossmatch incompatibilities were observed between recipient's plasma and all 61 DEA 1+ crossmatched controls. Moderate to weak incompatibilities were also observed to DEA 1- controls. Anti-DEA 1 and other alloantibodies were detected over the 4.5 year observation period. Blood from a weakly DEA 1+ donor induces a strong and durable alloimmunization in a DEA 1- recipient dog. Additional alloantibodies developed against yet to be defined RBC Antigens. Those results support the recommendation of typing dogs against DEA 1, considering weakly DEA 1+ as immunogenic, and crossmatching all previously transfused dogs. © 2019 The Authors. Journal of Veterinary Internal Medicine published by Wiley Periodicals, Inc. on behalf of the American College of Veterinary Internal Medicine.
-
Dog Erythrocyte Antigen 1: mode of inheritance and initial characterization
Veterinary clinical pathology, 2015Co-Authors: Klaudia Polak, Michelle M. Acierno, Karthik Raj, Keijiro Mizukami, Don L. Siegel, Urs GigerAbstract:Background The dog Erythrocyte Antigen (DEA) 1 blood group system remains poorly defined. Objectives The purpose of the study was to determine the DEA 1 mode of inheritance and to characterize the DEA 1 Antigen and alloantibodies. Animals Canine research colony families, clinic canine patients, and DEA 1.2+ blood bank dogs were studied. Methods Canine blood was typed by flow cytometry and immunochromatographic strips using anti-DEA 1 monoclonal antibodies. Gel column experiments with polyclonal and immunoblotting with monoclonal anti-DEA 1 antibodies were performed to analyze select samples. Cross-reactivity of human typing reagents against canine RBC and one monoclonal anti-DEA 1 antibody against human RBC panels was assessed. Results Typing of 12 families comprising 144 dogs indicated an autosomal dominant inheritance with ≥ 4 alleles: DEA 1− (0) and DEA 1+ weak (1+), intermediate (2+), and strong (3+ and 4+). Samples from 6 dogs previously typed as DEA 1.2+ were typed as DEA 1+ or DEA 1− using monoclonal antibodies. Human typing reagents produced varied reactions in tube agglutination experiments against DEA 1+ and DEA 1− RBC. Polypeptide bands were not detected on immunoblots using a monoclonal anti-DEA 1 antibody, therefore the anti-DEA 1 antibody may be specific for conformational epitopes lost during processing. Conclusions The autosomal dominant inheritance of DEA 1 with ≥ 4 alleles indicates a complex blood group system; the Antigenicity of each DEA 1+ type will need to be determined. The biochemical nature of the DEA 1 Antigen(s) appears different from human blood group systems tested.
-
comparison of gel column card and cartridge techniques for dog Erythrocyte Antigen 1 1 blood typing
American Journal of Veterinary Research, 2012Co-Authors: Mayank Seth, Karen V Jackson, Sarah Winzelberg, Urs GigerAbstract:Objective—To compare accuracy and ease of use of a card agglutination assay, an immunochromatographic cartridge method, and a gel-based method for canine blood typing. Sample—Blood samples from 52 healthy blood donor dogs, 10 dogs with immune-mediated hemolytic anemia (IMHA), and 29 dogs with other diseases. Procedures—Blood samples were tested in accordance with manufacturer guidelines. Samples with low PCVs were created by the addition of autologous plasma to separately assess the effects of anemia on test results. Results—Compared with a composite reference standard of agreement between 2 methods, the gel-based method was found to be 100% accurate. The card agglutination assay was 89% to 91% accurate, depending on test interpretation, and the immunochromatographic cartridge method was 93% accurate but 100% specific. Errors were observed more frequently in samples from diseased dogs, particularly those with IMHA. In the presence of persistent autoagglutination, dog Erythrocyte Antigen (DEA) 1.1 typing w...
-
Comparison of gel column, card, and cartridge techniques for dog Erythrocyte Antigen 1.1 blood typing
American journal of veterinary research, 2012Co-Authors: Mayank Seth, Karen V Jackson, Sarah Winzelberg, Urs GigerAbstract:To compare accuracy and ease of use of a card agglutination assay, an immunochromatographic cartridge method, and a gel-based method for canine blood typing. Blood samples from 52 healthy blood donor dogs, 10 dogs with immune-mediated hemolytic anemia (IMHA), and 29 dogs with other diseases. Blood samples were tested in accordance with manufacturer guidelines. Samples with low PCVs were created by the addition of autologous plasma to separately assess the effects of anemia on test results. Compared with a composite reference standard of agreement between 2 methods, the gel-based method was found to be 100% accurate. The card agglutination assay was 89% to 91% accurate, depending on test interpretation, and the immunochromatographic cartridge method was 93% accurate but 100% specific. Errors were observed more frequently in samples from diseased dogs, particularly those with IMHA. In the presence of persistent autoagglutination, dog Erythrocyte Antigen (DEA) 1.1 typing was not possible, except with the immunochromatographic cartridge method. The card agglutination assay and immunochromatographic cartridge method, performed by trained personnel, were suitable for in-clinic emergency DEA 1.1 blood typing. There may be errors, particularly for samples from dogs with IMHA, and the immunochromatographic cartridge method may have an advantage of allowing typing of samples with persistent autoagglutination. The laboratory gel-based method would be preferred for routine DEA 1.1 typing of donors and patients if it is available and time permits. Current DEA 1.1 typing techniques appear to be appropriately standardized and easy to use.
Jonathan F. Mcanulty - One of the best experts on this subject based on the ideXlab platform.
-
Use of capecitabine to prevent acute renal allograft rejection in dog Erythrocyte Antigen-mismatched mongrel dogs.
Veterinary surgery : VS, 2007Co-Authors: Milan Milovancev, Chad W. Schmiedt, Michelle Schwab, Richard R. Dubielzig, Ellison Bentley, Annette Gendron-fitzpatrick, Jonathan F. McanultyAbstract:To assess efficacy and toxicity of a capecitabine (CAP)-based regimen for preventing rejection of renal allografts in dog Erythrocyte Antigen (DEA)-mismatched mongrel dogs. Prospective, pilot study. Eight healthy, unrelated, DEA mismatched, adult mongrel dogs. All dogs received CAP, starting at 50 mg/m2 PO b.i.d. 4 days preoperatively, increasing to 200 mg/m2 PO b.i.d. by the day of surgery. All dogs received cyclosporine-A (CsA) and prednisolone starting 2 days preoperatively. Standard heterotopic renal transplantation with native nephrectomy was performed. After 90 days, surviving dogs were euthanatized and histopathologic examination was performed. Two of 8 dogs developed acute neurotoxicity leading to death or euthanasia within 5 days of surgery. For the 6 remaining dogs, there were no statistically significant changes in complete blood count or serum biochemical values. No opportunistic infections developed during the study period. Five of 6 dogs had no to minimal evidence of graft rejection. Two of 6 dogs developed superficial and pigmentary keratitis. Significant histopathologic findings in all dogs included mild lymphoplasmacytic gastroenteritis, steroid hepatopathy, and corneal epithelial thinning. One dog had moderate interstitial nephritis and pyelitis. In this experimental model, a CAP-CsA-prednisolone immunosuppressive regimen was effective in preventing rejection of allografts in DEA-mismatched dogs. Severe, unpredictable neurotoxicity and variable ocular toxicity significantly limit clinical applications at this time. A CAP-CsA-prednisolone protocol is an effective, oral immunosuppressive regimen for prevention of allograft rejection in DEA-mismatched mongrel dogs. For clinical application, identification of patients susceptible to toxic side effects would be necessary.
-
use of capecitabine to prevent acute renal allograft rejection in dog Erythrocyte Antigen mismatched mongrel dogs
Veterinary Surgery, 2007Co-Authors: Milan Milovancev, Chad W. Schmiedt, Michelle Schwab, Richard R. Dubielzig, Ellison Bentley, Annette Gendronfitzpatrick, Jonathan F. McanultyAbstract:Objective— To assess efficacy and toxicity of a capecitabine (CAP)-based regimen for preventing rejection of renal allografts in dog Erythrocyte Antigen (DEA)-mismatched mongrel dogs. Study Design— Prospective, pilot study. Animals— Eight healthy, unrelated, DEA mismatched, adult mongrel dogs. Methods— All dogs received CAP, starting at 50 mg/m2 PO b.i.d. 4 days preoperatively, increasing to 200 mg/m2 PO b.i.d. by the day of surgery. All dogs received cyclosporine-A (CsA) and prednisolone starting 2 days preoperatively. Standard heterotopic renal transplantation with native nephrectomy was performed. After 90 days, surviving dogs were euthanatized and histopathologic examination was performed. Results— Two of 8 dogs developed acute neurotoxicity leading to death or euthanasia within 5 days of surgery. For the 6 remaining dogs, there were no statistically significant changes in complete blood count or serum biochemical values. No opportunistic infections developed during the study period. Five of 6 dogs had no to minimal evidence of graft rejection. Two of 6 dogs developed superficial and pigmentary keratitis. Significant histopathologic findings in all dogs included mild lymphoplasmacytic gastroenteritis, steroid hepatopathy, and corneal epithelial thinning. One dog had moderate interstitial nephritis and pyelitis. Conclusions— In this experimental model, a CAP–CsA–prednisolone immunosuppressive regimen was effective in preventing rejection of allografts in DEA-mismatched dogs. Severe, unpredictable neurotoxicity and variable ocular toxicity significantly limit clinical applications at this time. Clinical Relevance— A CAP–CsA–prednisolone protocol is an effective, oral immunosuppressive regimen for prevention of allograft rejection in DEA-mismatched mongrel dogs. For clinical application, identification of patients susceptible to toxic side effects would be necessary.
-
use of capecitabine after renal allograft transplantation in dog Erythrocyte Antigen matched dogs
Veterinary Surgery, 2006Co-Authors: Chad W. Schmiedt, Chiara Penzo, Michelle Schwab, Richard R. Dubielzig, Jonathan F. McanultyAbstract:Objectives— To investigate the use of a capecitabine (CAP)-based regimen after renal transplantation in dogs. Study Design— Prospective, pilot study. Animals— Healthy, unrelated, dog Erythrocyte Antigen (DEA)-matched, adult beagles. Method— Standard heterotopic renal transplantation with native nephrectomy was performed in 7 dogs. Dogs received oral, twice daily, CAP (250 mg/m2), cyclosporine-A (CsA) (4 mg/kg), ketoconazole (5 mg/kg), and prednisolone (0.25 mg/kg). After 90 days the surviving dogs were euthanatized and complete necropsy was performed. Results— Seven transplants were performed. All dogs survived surgery. Six dogs had acute neurotoxicity, which resulted in death or euthanasia of 2 dogs within 2 days of surgery. In the remaining dogs, toxicity resolved rapidly with cessation of drug administration. Thereafter, modification of the regimen minimized toxicity. The 5 remaining dogs survived to study end; 4 dogs had no evidence of graft rejection. Necropsy examination was mostly unremarkable in all dogs. There were no major changes in CBC or biochemical values, except for a significant increase in serum calcium. Conclusions— CAP appeared well tolerated in most dogs. Toxicity occurred but abated with modification of the drug regimen. Efficacy for postoperative immunosuppression cannot be determined by this study, although results are promising. Clinical Relevance— CAP-CsA-prednisolone is an effective, oral immunosuppressive regimen for prevention of acute allograft rejection in DEA-matched beagles. Further studies on dose, toxicity, and efficacy compared with current immunosuppressive regimens are needed before use in clinical practice.
-
Use of Capecitabine After Renal Allograft Transplantation in Dog Erythrocyte Antigen‐Matched Dogs
Veterinary surgery : VS, 2006Co-Authors: Chad W. Schmiedt, Chiara Penzo, Michelle Schwab, Richard R. Dubielzig, Jonathan F. McanultyAbstract:Objectives— To investigate the use of a capecitabine (CAP)-based regimen after renal transplantation in dogs. Study Design— Prospective, pilot study. Animals— Healthy, unrelated, dog Erythrocyte Antigen (DEA)-matched, adult beagles. Method— Standard heterotopic renal transplantation with native nephrectomy was performed in 7 dogs. Dogs received oral, twice daily, CAP (250 mg/m2), cyclosporine-A (CsA) (4 mg/kg), ketoconazole (5 mg/kg), and prednisolone (0.25 mg/kg). After 90 days the surviving dogs were euthanatized and complete necropsy was performed. Results— Seven transplants were performed. All dogs survived surgery. Six dogs had acute neurotoxicity, which resulted in death or euthanasia of 2 dogs within 2 days of surgery. In the remaining dogs, toxicity resolved rapidly with cessation of drug administration. Thereafter, modification of the regimen minimized toxicity. The 5 remaining dogs survived to study end; 4 dogs had no evidence of graft rejection. Necropsy examination was mostly unremarkable in all dogs. There were no major changes in CBC or biochemical values, except for a significant increase in serum calcium. Conclusions— CAP appeared well tolerated in most dogs. Toxicity occurred but abated with modification of the drug regimen. Efficacy for postoperative immunosuppression cannot be determined by this study, although results are promising. Clinical Relevance— CAP-CsA-prednisolone is an effective, oral immunosuppressive regimen for prevention of acute allograft rejection in DEA-matched beagles. Further studies on dose, toxicity, and efficacy compared with current immunosuppressive regimens are needed before use in clinical practice.
Maryline Guidetti - One of the best experts on this subject based on the ideXlab platform.
-
The dog Erythrocyte Antigen 1 blood group in nondomesticated canids and compatibility testing between domestic dog and nondomesticated canid blood.
Journal of veterinary internal medicine, 2020Co-Authors: Thomas Charpentier, Maryline Guidetti, Thierry Petit, Isabelle Goy-thollotAbstract:Background The dog Erythrocyte Antigen (DEA) 1 blood group is considered as the most immunogenic and clinically important in dogs. Little is known in nondomesticated canids. Objectives To type DEA 1 in nondomesticated captive canids and to evaluate potential interspecific blood transfusions between domestic and nondomestic canids. Animals One hundred forty captive nondomesticated canids belonging to 13 species from 19 French zoos, and 63 domestic dogs. Methods Prospective study. Blood samples were typed for DEA 1 using immunochromatographic and flow cytometric techniques. A neutral gel column test was used for crossmatching. Results Of 140 nondomesticated canids, 72.9% were DEA 1+ and 27.1% were DEA 1- using immunochromatographic technique and 74.3% were DEA 1+ and 25.7% were DEA 1- by flow cytometric technique. Crossmatch (XM) between 140 nondomesticated canid red blood cells (RBCs) and plasma from a previously DEA 1+ sensitized DEA 1- dog revealed 112 incompatibilities (80%). Crossmatches between 130 nondomesticated canid serum and 1 or up to 8 donor dogs' RBCs revealed 99 of 130 (76%) compatibilities. Crossmatches between 115 nondomesticated canid RBCs and donor dogs' serum revealed 59 of 115 (51%) compatibilities. Conclusions and clinical importance Dog Erythrocyte Antigen 1 blood type is present in nondomesticated canids with variable prevalence depending on species. The majority of tested nondomesticated canids appear to have no naturally occurring alloantibodies against domestic dogs' RBCs. Therefore xenotransfusion of blood from domestic dogs can be considered when species specific blood is not available. Cross matching is essential before xenotransfusion.
-
alloimmunization of a dog Erythrocyte Antigen 1 dog transfused with weakly dog Erythrocyte Antigen 1 blood
Journal of Veterinary Internal Medicine, 2019Co-Authors: Maryline Guidetti, Isabelle Goythollot, Catherine Boisvineau, Urs GigerAbstract:Background Acute hemolytic transfusion reactions because of dog Erythrocyte Antigen (DEA) 1 sensitization after mismatched transfusions are serious complications. Dog Erythrocyte Antigen 1 expression varies from negative to weakly to strongly positive. Objectives To assess alloimmunization after transfusion of weakly DEA 1+ blood to a DEA 1- dog. Animals One DEA 1- recipient and 1 weakly DEA 1+ donor, and 106 control dogs. Methods Long-term follow-up study. Matched for DEA 3, 4, 5, and 7, Dal, and Kai 1 and 2, weakly DEA 1+ donor packed red blood cells (RBCs) were transfused 3 times (0.45 mL/kg at Day 0, 16, and 37) to a DEA 1- recipient. Alloantibodies against RBCs from donor and 106 controls were determined in recipient's plasma samples using a commercial antiglobulin-enhanced immunochromatographic strip and gel tube crossmatches. Alloantibody titers were determined. Results The DEA 1- recipient was sensitized after 16 days to ≥1657 days after transfusion to weakly DEA 1+ and otherwise matched RBCs. Strong to moderate crossmatch incompatibilities were observed between recipient's plasma and all 61 DEA 1+ crossmatched controls. Moderate to weak incompatibilities were also observed to DEA 1- controls. Anti-DEA 1 and other alloantibodies were detected over the 4.5 year observation period. Conclusions and clinical importance Blood from a weakly DEA 1+ donor induces a strong and durable alloimmunization in a DEA 1- recipient dog. Additional alloantibodies developed against yet to be defined RBC Antigens. Those results support the recommendation of typing dogs against DEA 1, considering weakly DEA 1+ as immunogenic, and crossmatching all previously transfused dogs.
-
Alloimmunization of a dog Erythrocyte Antigen 1− dog transfused with weakly dog Erythrocyte Antigen 1+ blood
Journal of veterinary internal medicine, 2019Co-Authors: Maryline Guidetti, Catherine Boisvineau, Isabelle Goy-thollot, Urs GigerAbstract:Acute hemolytic transfusion reactions because of dog Erythrocyte Antigen (DEA) 1 sensitization after mismatched transfusions are serious complications. Dog Erythrocyte Antigen 1 expression varies from negative to weakly to strongly positive. To assess alloimmunization after transfusion of weakly DEA 1+ blood to a DEA 1- dog. One DEA 1- recipient and 1 weakly DEA 1+ donor, and 106 control dogs. Long-term follow-up study. Matched for DEA 3, 4, 5, and 7, Dal, and Kai 1 and 2, weakly DEA 1+ donor packed red blood cells (RBCs) were transfused 3 times (0.45 mL/kg at Day 0, 16, and 37) to a DEA 1- recipient. Alloantibodies against RBCs from donor and 106 controls were determined in recipient's plasma samples using a commercial antiglobulin-enhanced immunochromatographic strip and gel tube crossmatches. Alloantibody titers were determined. The DEA 1- recipient was sensitized after 16 days to ≥1657 days after transfusion to weakly DEA 1+ and otherwise matched RBCs. Strong to moderate crossmatch incompatibilities were observed between recipient's plasma and all 61 DEA 1+ crossmatched controls. Moderate to weak incompatibilities were also observed to DEA 1- controls. Anti-DEA 1 and other alloantibodies were detected over the 4.5 year observation period. Blood from a weakly DEA 1+ donor induces a strong and durable alloimmunization in a DEA 1- recipient dog. Additional alloantibodies developed against yet to be defined RBC Antigens. Those results support the recommendation of typing dogs against DEA 1, considering weakly DEA 1+ as immunogenic, and crossmatching all previously transfused dogs. © 2019 The Authors. Journal of Veterinary Internal Medicine published by Wiley Periodicals, Inc. on behalf of the American College of Veterinary Internal Medicine.
C. Guillermo Couto - One of the best experts on this subject based on the ideXlab platform.
-
Prevalence of dog Erythrocyte Antigens in retired racing Greyhounds
Veterinary Clinical Pathology, 2010Co-Authors: M.c. Iazbik, L.m. Marín, Margee O'donnell, Sara Zaldivar, Dawn Hudson, C. Guillermo CoutoAbstract:Background: Blood groups in dogs are designated as dog Erythrocyte Antigen (DEA) 1.1, 1.2, 3, 4, 5, 7, and Dal. There is limited information about the frequency of different Antigens in Greyhound dogs, despite their frequent use as blood donors. Objectives: The aims of this study were to determine the frequencies of DEA 1.1, 1.2, 3, 4, 5, and 7 in Greyhounds, to compare the frequencies with those of non-Greyhound dogs, and to evaluate the presence of naturally occurring anti-DEA antibodies. Methods: Blood was collected from 206 Greyhound and 66 non-Greyhound dogs being screened as potential blood donors. Blood-typing was performed at Animal Blood Resources International by tube agglutination utilizing polyclonal anti-DEA antibodies. Results: Of the Greyhound dogs, 27/206 (13.1%) were positive for DEA 1.1, and this frequency was significantly lower (P
-
Prevalence of dog Erythrocyte Antigens in retired racing Greyhounds
Veterinary clinical pathology, 2010Co-Authors: M.c. Iazbik, L.m. Marín, Margee O'donnell, Sara Zaldivar, Dawn Hudson, C. Guillermo CoutoAbstract:Blood groups in dogs are designated as dog Erythrocyte Antigen (DEA) 1.1, 1.2, 3, 4, 5, 7, and Dal. There is limited information about the frequency of different Antigens in Greyhound dogs, despite their frequent use as blood donors. The aims of this study were to determine the frequencies of DEA 1.1, 1.2, 3, 4, 5, and 7 in Greyhounds, to compare the frequencies with those of non-Greyhound dogs, and to evaluate the presence of naturally occurring anti-DEA antibodies. Blood was collected from 206 Greyhound and 66 non-Greyhound dogs being screened as potential blood donors. Blood-typing was performed at Animal Blood Resources International by tube agglutination utilizing polyclonal anti-DEA antibodies. Of the Greyhound dogs, 27/206 (13.1%) were positive for DEA 1.1, and this frequency was significantly lower (P<.0001) than for non-Greyhound dogs of which 40/66 (60.6%) were DEA 1.1-positive. The frequency of positivity for both DEA 1.1 and 1.2 was also lower in Greyhounds (P<.0001). There were no significant differences between Greyhounds and non-Greyhounds for DEA 1.2, 3, 4, 5, or 7. All 137 dogs (113 Greyhounds and 24 non-Greyhounds) that were evaluated for naturally occurring anti-DEA antibodies in serum were negative. A higher percentage of Greyhound dogs (57.3%, 118/206) were considered "universal donors" (negative for all DEAs except DEA 4) compared with non-Greyhound dogs (28%, 13/46). The frequency of positivity for DEA 1.1 in our population of Greyhounds was significantly lower than previously reported for dogs. Furthermore, a large majority of Greyhounds met the criteria for universal donors. ©2010 American Society for Veterinary Clinical Pathology.
Chad W. Schmiedt - One of the best experts on this subject based on the ideXlab platform.
-
Use of capecitabine to prevent acute renal allograft rejection in dog Erythrocyte Antigen-mismatched mongrel dogs.
Veterinary surgery : VS, 2007Co-Authors: Milan Milovancev, Chad W. Schmiedt, Michelle Schwab, Richard R. Dubielzig, Ellison Bentley, Annette Gendron-fitzpatrick, Jonathan F. McanultyAbstract:To assess efficacy and toxicity of a capecitabine (CAP)-based regimen for preventing rejection of renal allografts in dog Erythrocyte Antigen (DEA)-mismatched mongrel dogs. Prospective, pilot study. Eight healthy, unrelated, DEA mismatched, adult mongrel dogs. All dogs received CAP, starting at 50 mg/m2 PO b.i.d. 4 days preoperatively, increasing to 200 mg/m2 PO b.i.d. by the day of surgery. All dogs received cyclosporine-A (CsA) and prednisolone starting 2 days preoperatively. Standard heterotopic renal transplantation with native nephrectomy was performed. After 90 days, surviving dogs were euthanatized and histopathologic examination was performed. Two of 8 dogs developed acute neurotoxicity leading to death or euthanasia within 5 days of surgery. For the 6 remaining dogs, there were no statistically significant changes in complete blood count or serum biochemical values. No opportunistic infections developed during the study period. Five of 6 dogs had no to minimal evidence of graft rejection. Two of 6 dogs developed superficial and pigmentary keratitis. Significant histopathologic findings in all dogs included mild lymphoplasmacytic gastroenteritis, steroid hepatopathy, and corneal epithelial thinning. One dog had moderate interstitial nephritis and pyelitis. In this experimental model, a CAP-CsA-prednisolone immunosuppressive regimen was effective in preventing rejection of allografts in DEA-mismatched dogs. Severe, unpredictable neurotoxicity and variable ocular toxicity significantly limit clinical applications at this time. A CAP-CsA-prednisolone protocol is an effective, oral immunosuppressive regimen for prevention of allograft rejection in DEA-mismatched mongrel dogs. For clinical application, identification of patients susceptible to toxic side effects would be necessary.
-
use of capecitabine to prevent acute renal allograft rejection in dog Erythrocyte Antigen mismatched mongrel dogs
Veterinary Surgery, 2007Co-Authors: Milan Milovancev, Chad W. Schmiedt, Michelle Schwab, Richard R. Dubielzig, Ellison Bentley, Annette Gendronfitzpatrick, Jonathan F. McanultyAbstract:Objective— To assess efficacy and toxicity of a capecitabine (CAP)-based regimen for preventing rejection of renal allografts in dog Erythrocyte Antigen (DEA)-mismatched mongrel dogs. Study Design— Prospective, pilot study. Animals— Eight healthy, unrelated, DEA mismatched, adult mongrel dogs. Methods— All dogs received CAP, starting at 50 mg/m2 PO b.i.d. 4 days preoperatively, increasing to 200 mg/m2 PO b.i.d. by the day of surgery. All dogs received cyclosporine-A (CsA) and prednisolone starting 2 days preoperatively. Standard heterotopic renal transplantation with native nephrectomy was performed. After 90 days, surviving dogs were euthanatized and histopathologic examination was performed. Results— Two of 8 dogs developed acute neurotoxicity leading to death or euthanasia within 5 days of surgery. For the 6 remaining dogs, there were no statistically significant changes in complete blood count or serum biochemical values. No opportunistic infections developed during the study period. Five of 6 dogs had no to minimal evidence of graft rejection. Two of 6 dogs developed superficial and pigmentary keratitis. Significant histopathologic findings in all dogs included mild lymphoplasmacytic gastroenteritis, steroid hepatopathy, and corneal epithelial thinning. One dog had moderate interstitial nephritis and pyelitis. Conclusions— In this experimental model, a CAP–CsA–prednisolone immunosuppressive regimen was effective in preventing rejection of allografts in DEA-mismatched dogs. Severe, unpredictable neurotoxicity and variable ocular toxicity significantly limit clinical applications at this time. Clinical Relevance— A CAP–CsA–prednisolone protocol is an effective, oral immunosuppressive regimen for prevention of allograft rejection in DEA-mismatched mongrel dogs. For clinical application, identification of patients susceptible to toxic side effects would be necessary.
-
use of capecitabine after renal allograft transplantation in dog Erythrocyte Antigen matched dogs
Veterinary Surgery, 2006Co-Authors: Chad W. Schmiedt, Chiara Penzo, Michelle Schwab, Richard R. Dubielzig, Jonathan F. McanultyAbstract:Objectives— To investigate the use of a capecitabine (CAP)-based regimen after renal transplantation in dogs. Study Design— Prospective, pilot study. Animals— Healthy, unrelated, dog Erythrocyte Antigen (DEA)-matched, adult beagles. Method— Standard heterotopic renal transplantation with native nephrectomy was performed in 7 dogs. Dogs received oral, twice daily, CAP (250 mg/m2), cyclosporine-A (CsA) (4 mg/kg), ketoconazole (5 mg/kg), and prednisolone (0.25 mg/kg). After 90 days the surviving dogs were euthanatized and complete necropsy was performed. Results— Seven transplants were performed. All dogs survived surgery. Six dogs had acute neurotoxicity, which resulted in death or euthanasia of 2 dogs within 2 days of surgery. In the remaining dogs, toxicity resolved rapidly with cessation of drug administration. Thereafter, modification of the regimen minimized toxicity. The 5 remaining dogs survived to study end; 4 dogs had no evidence of graft rejection. Necropsy examination was mostly unremarkable in all dogs. There were no major changes in CBC or biochemical values, except for a significant increase in serum calcium. Conclusions— CAP appeared well tolerated in most dogs. Toxicity occurred but abated with modification of the drug regimen. Efficacy for postoperative immunosuppression cannot be determined by this study, although results are promising. Clinical Relevance— CAP-CsA-prednisolone is an effective, oral immunosuppressive regimen for prevention of acute allograft rejection in DEA-matched beagles. Further studies on dose, toxicity, and efficacy compared with current immunosuppressive regimens are needed before use in clinical practice.
-
Use of Capecitabine After Renal Allograft Transplantation in Dog Erythrocyte Antigen‐Matched Dogs
Veterinary surgery : VS, 2006Co-Authors: Chad W. Schmiedt, Chiara Penzo, Michelle Schwab, Richard R. Dubielzig, Jonathan F. McanultyAbstract:Objectives— To investigate the use of a capecitabine (CAP)-based regimen after renal transplantation in dogs. Study Design— Prospective, pilot study. Animals— Healthy, unrelated, dog Erythrocyte Antigen (DEA)-matched, adult beagles. Method— Standard heterotopic renal transplantation with native nephrectomy was performed in 7 dogs. Dogs received oral, twice daily, CAP (250 mg/m2), cyclosporine-A (CsA) (4 mg/kg), ketoconazole (5 mg/kg), and prednisolone (0.25 mg/kg). After 90 days the surviving dogs were euthanatized and complete necropsy was performed. Results— Seven transplants were performed. All dogs survived surgery. Six dogs had acute neurotoxicity, which resulted in death or euthanasia of 2 dogs within 2 days of surgery. In the remaining dogs, toxicity resolved rapidly with cessation of drug administration. Thereafter, modification of the regimen minimized toxicity. The 5 remaining dogs survived to study end; 4 dogs had no evidence of graft rejection. Necropsy examination was mostly unremarkable in all dogs. There were no major changes in CBC or biochemical values, except for a significant increase in serum calcium. Conclusions— CAP appeared well tolerated in most dogs. Toxicity occurred but abated with modification of the drug regimen. Efficacy for postoperative immunosuppression cannot be determined by this study, although results are promising. Clinical Relevance— CAP-CsA-prednisolone is an effective, oral immunosuppressive regimen for prevention of acute allograft rejection in DEA-matched beagles. Further studies on dose, toxicity, and efficacy compared with current immunosuppressive regimens are needed before use in clinical practice.
